MYBL2 (v-myb myeloblastosis viral oncogene homolog (avian)-like 2)

2008-10-01 Olesya Chayka , Arturo Sala Affiliation

Institute of Child Health Molecular Haematology, Cancer Biology Unit 30 Guilford street London, WC1N 1EH UK

Identity

HGNC

MYBL2

LOCATION

20q13.12

LOCUSID

4605

ALIAS

B-MYB,BMYB

FUSION GENES

Show Gene Fusions

DNA/RNA

red boxes: untranslated regions; green boxes: coding regions.

Description

49,415 bases DNA with 14 exons.

Transcription

2,731 bases mRNA.

Proteins

R1, R2 and R3 form DNA-binding domain, TA - transactivation domain, CR - conserved region (the area of homology with c-Myb), RD - regulatory domain.

Description

704 amino acids, 93kDa protein.
R1, R2, R3 - three repeats 50 amino acids long, R2 and R3 contain HTH (helix-turn-helix) motives with unconventional turns required for DNA-binding activity, R1 serves as a DNA/protein complex stabilizer; TA contains acidic amino acids and is responsible for transcriptional activation; RD is responsible for repression of transactivation function of B-MYB.

Expression

Widely expressed, expression is very high in proliferative cells, embryonic cells, haematopoietic progenitor cells.

Localisation

Nucleus.

Function

Transcription factor required for cell proliferation, cell cycle progression, chromosomal stability and differentiation. B-MYB knockout mice die at E4.5-E6.5 due to early developmental arrest.

Homology

B-MYB is a member of MYB transcription factors family, which includes C-MYB and A-MYB, with high homology within TA and RD regions. DNA-binding domain is almost identical with that of A-MYB and C-MYB and conserved between mouse, human, chicken and drosophila.

Implicated in

Entity name

Neuroblastoma

Prognosis

Overexpression is thought to be associated with a poor outcome of the disease.

Oncogenesis

Was reported to be necessary for survival and differentiation of neuroblastoma cells.

Entity name

Hepatocellular carcinoma (HCC)

Oncogenesis

B-MYB is reported to be a probable target of E2F1 transcription factor, which is dramatically overexpressed in HCC. There is a clear correlation between expression level of these two proteins. B-MYB overexpression in HCC causes the deregulation of apoptosis and cell cycle.

Entity name

Various cancer

Disease

Amplification of B-MYB was described in breast carcinomas, liver carcinomas, ovarian carcinomas and in cutaneous T lymphoma. B-MYB expression was shown also to be increased in prostate and testicular malignancies. Moreover, B-MYB expression is notably increased in metastatic compared to localised prostate tumours.
The presence of B-MYB polymorphisms rs2070235 and rs11556379 is associated with a significant reduction of cancer risk.

Oncogenesis

B-MYB overexpression may result in promotion of cancer cells survival and proliferation.
Polimorphisms can induce changes in protein conformation and therefore may in part deactivate B-MYB functions.

Article Bibliography

Pubmed ID	Last Year	Title	Authors
18624722	2008	Activation of B-Myb by E2F1 in hepatocellular carcinoma.	Nakajima T et al
8812502	1996	Mybl2 (Bmyb) maps to mouse chromosome 2 and human chromosome 20q 13.1.	Noben-Trauth K et al
10378697	1999	The myb gene family in cell growth, differentiation and apoptosis.	Oh IH et al
7721753	1995	Requirement of b-myb function for survival and differentiative potential of human neuroblastoma cells.	Raschellà G et al
10416595	1999	Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.	Raschellà G et al
10228942	1999	B-Myb protein in cellular proliferation, transcription control, and cancer: latest developments.	Sala A et al
18026132	2008	Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk.	Schwab R et al
17588787	2007	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: implications for cell survival.	Schwab R et al
10497154	1999	B-myb is required for inner cell mass formation at an early stage of development.	Tanaka Y et al

Other Information

Locus ID:

NCBI: 4605
MIM: 601415
HGNC: 7548
Ensembl: ENSG00000101057

Variants:

dbSNP: 4605
ClinVar: 4605
TCGA: ENSG00000101057
COSMIC: MYBL2

RNA/Proteins

Gene ID	Transcript ID	Uniprot
ENSG00000101057	ENST00000217026	P10244
ENSG00000101057	ENST00000396863	P10244

Expression (GTEx)

100

150

200

Adipose - Subcutaneous

Adipose - Visceral

Adrenal Gland

Artery - Aorta

Artery - Tibial

Bladder

Brain - Amygdala

Brain - Anterior cingulate cortex

Brain - Caudate

Brain - Cerebellar Hemisphere

Brain - Cerebellum

Brain - Cortex

Brain - Frontal Cortex

Brain - Hippocampus

Brain - Hypothalamus

Brain - Nucleus accumbens

Brain - Putamen

Brain - Spinal cord

Brain - Substantia nigra

Breast - Mammary Tissue

Cells - Cultured fibroblasts

Cells - EBV - transformed lymphocytes

Cervix - Ectocervix

Cervix - Endocervix

Colon - Sigmoid

Colon - Transverse

Esophagus - Gastroesophageal Junction

Esophagus - Mucosa

Esophagus - Muscularis

Fallopian Tube

Heart - Atrial Appendage

Heart - Left Ventricle

Kidney - Cortex

Kidney - Medulla

Liver

Lung

Minor Salivary Gland

Muscle - Skeletal

Nerve - Tibial

Ovary

Pancreas

Pituitary

Prostate

Skin - Not Sun Exposed

Skin - Sun Exposed

Small Intestine - Terminal Ileum

Spleen

Stomach

Testis

Thyroid

Uterus

Vagina

Whole Blood

Pathways

Pathway	Source	External ID
HTLV-I infection	KEGG	ko05166
HTLV-I infection	KEGG	hsa05166
Gene Expression	REACTOME	R-HSA-74160
Generic Transcription Pathway	REACTOME	R-HSA-212436
Cell Cycle	REACTOME	R-HSA-1640170
Cell Cycle, Mitotic	REACTOME	R-HSA-69278
Mitotic G1-G1/S phases	REACTOME	R-HSA-453279
G0 and Early G1	REACTOME	R-HSA-1538133
Mitotic G2-G2/M phases	REACTOME	R-HSA-453274
G2/M Transition	REACTOME	R-HSA-69275
Polo-like kinase mediated events	REACTOME	R-HSA-156711
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	REACTOME	R-HSA-8864260
TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation	REACTOME	R-HSA-8869496

Protein levels (Protein atlas)

Not detected

Low

Medium

High

References

Pubmed ID	Year	Title	Citations
38182898	2024	Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.	0
38336287	2024	Up-regulation of RAN by MYBL2 maintains osteosarcoma cancer stem-like cells population during heterogeneous tumor generation.	0
38182898	2024	Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers.	0
38336287	2024	Up-regulation of RAN by MYBL2 maintains osteosarcoma cancer stem-like cells population during heterogeneous tumor generation.	0
36812959	2023	Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.	6
36854682	2023	Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer.	3
37030434	2023	Up-regulation of ABCG2 by MYBL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer.	3
36812959	2023	Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.	6
36854682	2023	Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer.	3
37030434	2023	Up-regulation of ABCG2 by MYBL2 deletion drives Chlorin e6-mediated photodynamic therapy resistance in colorectal cancer.	3
35135230	2022	Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.	7
35176941	2022	MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the Optic atrophy 3 promoter and activating its expression.	4
35341461	2022	Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells.	3
35557985	2022	LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.	8
36071275	2022	MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3.	12

Citation

Olesya Chayka ; Arturo Sala

MYBL2 (v-myb myeloblastosis viral oncogene homolog (avian)-like 2)

Atlas Genet Cytogenet Oncol Haematol. 2008-10-01

Online version: http://atlasgeneticsoncology.org/gene/41469